Istradefylline is a prescription medicine indicated as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson's disease (PD) experiencing "off" episodes. It is available as tablets for oral use. MedsAcross supplies Istradefylline for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
NOURIANZ is indicated as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson's disease (PD) experiencing "off" episodes. NOURIANZ is an adenosine receptor antagonist indicated as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson's disease (PD) experiencing "off" episodes.
Source: US FDA prescribing information
The precise mechanism by which istradefylline exerts its therapeutic effect in Parkinson’s disease is unknown. In in vitro studies and in in vivo animal studies, istradefylline was demonstrated to be an adenosine A 2A receptor antagonist.
Source: US FDA prescribing information
The recommended dosage is 20 mg orally once daily. The dosage may be increased to a maximum of 40 mg once daily. May be taken with or without food. Patients with hepatic impairment: Maximum recommended dosage with moderate hepatic impairment is 20 mg once daily, use of NOURIANZ in patients with severe hepatic impairment should be avoided. Patients who smoke 20 or more cigarettes per day (or the equivalent of another tobacco product): Recommended dosage is 40 mg once daily.
Source: US FDA prescribing information
None. None.
Source: US FDA prescribing information
Dyskinesia: Monitor patients for dyskinesia or exacerbation of existing dyskinesia. Hallucinations / Psychotic Behavior: Consider dosage reduction or stopping NOURIANZ if occurs. Impulse Control / Compulsive Behaviors: Consider dosage reduction or stopping NOURIANZ if occurs.
Source: US FDA prescribing information
The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling: Dyskinesia Hallucinations / Psychotic Behavior Impulse Control / Compulsive Behaviors The most common adverse reactions (at least 5% and more frequent than placebo) were dyskinesia, dizziness, constipation, nausea, hallucination, and insomnia.
Source: US FDA prescribing information
Strong CYP3A4 inhibitors: Recommended maximum dosage with concomitant use is 20 mg once daily. Strong CYP3A4 inducers: Avoid use.
Source: US FDA prescribing information
Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (59°F to 86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
2 presentations of Istradefylline, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Nourianz 20 mg tabletOral | Kyowa Kirin | US FDA | Available on request |
| Nourianz 40 mg tabletOral | Kyowa Kirin | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 27 August 2019 | Drugs@FDA |
| EU (EMA) | Refused | EMA medicines data |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Istradefylline in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 2 presentations of Istradefylline and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Istradefylline, including Nourianz.
Yes. The US FDA first approved Istradefylline on 27 August 2019, according to Drugs@FDA.
No listed presentation of Istradefylline is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Istradefylline is classified under ATC code N04 (Parkinson's disease medicines).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.